- Angle-closure glaucoma, a serious ophthalmic condition characterized by a sudden rise in intraocular pressure due to blocked drainage angles in the eye, remains a leading cause of irreversible blindness, particularly in aging populations and certain ethnic groups such as East Asians and Inuits. Early detection and timely treatment are critical to prevent vision loss, making diagnostic accuracy and therapeutic innovation essential in managing the disease.
- The increasing prevalence of age-related eye disorders, rising healthcare awareness, and advances in diagnostic imaging techniques such as gonioscopy, tonometry, and anterior segment optical coherence tomography (AS-OCT) are driving market growth. Additionally, growing availability of surgical and pharmacological treatments is expanding patient access to effective disease management.
- Asia-Pacific dominates the angle-closure glaucoma market, accounting for the largest revenue share of over 38.5% in 2025, owing to a higher prevalence of the disease in the region, large aging population base, and increased government initiatives to support eye health. Countries such as China and India are witnessing significant improvements in screening infrastructure and awareness campaigns.
- North America is anticipated to show steady growth during the forecast period due to favorable reimbursement frameworks, high adoption of advanced ophthalmic technologies, and ongoing clinical research on novel therapies and combination treatments.
- The surgery segment is expected to lead the treatment category with a projected market share of 47.6% in 2025, driven by the increasing preference for laser peripheral iridotomy (LPI), trabeculectomy, and minimally invasive glaucoma surgery (MIGS) to reduce intraocular pressure in high-risk patients.
